These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37504297)

  • 1. EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.
    Voutsadakis IA
    Curr Issues Mol Biol; 2023 Jul; 45(7):6040-6054. PubMed ID: 37504297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.
    Voutsadakis IA
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.
    Voutsadakis IA
    Cancer Genomics Proteomics; 2023; 20(6):539-555. PubMed ID: 37889067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies.
    Voutsadakis IA
    Tissue Barriers; 2024 May; ():2348852. PubMed ID: 38713052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterisation of cell line models for triple-negative breast cancers.
    Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
    BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
    Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.
    Colavito SA; Zou MR; Yan Q; Nguyen DX; Stern DF
    Breast Cancer Res; 2014 Sep; 16(5):444. PubMed ID: 25252859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
    Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
    Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer.
    Khaled N; Bidet Y
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31003528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P
    BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.
    Sarrio D; Franklin CK; Mackay A; Reis-Filho JS; Isacke CM
    Stem Cells; 2012 Feb; 30(2):292-303. PubMed ID: 22102611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
    Logullo AF; Pasini FS; Nonogaki S; Rocha RM; Soares FA; Brentani MM
    Mol Clin Oncol; 2018 Oct; 9(4):377-388. PubMed ID: 30214726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
    Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
    Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
    Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
    Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.
    Dunlap SM; Chiao LJ; Nogueira L; Usary J; Perou CM; Varticovski L; Hursting SD
    Cancer Prev Res (Phila); 2012 Jul; 5(7):930-42. PubMed ID: 22588949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.
    Lee JL; Ekambaram P; Carleton NM; Hu D; Klei LR; Cai Z; Myers MI; Hubel NE; Covic L; Agnihotri S; Krappmann D; Bornancin F; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
    Mol Cancer Res; 2022 Mar; 20(3):373-386. PubMed ID: 34753803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
    Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
    Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin 1 expression in basal-like breast cancer is related to patient age.
    Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
    BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.